Influence of Extraperitoneal Metastases on the Curative-Intent Management of Colorectal Peritoneal Metastases.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
10
12
2022
accepted:
04
02
2023
medline:
12
6
2023
pubmed:
3
3
2023
entrez:
2
3
2023
Statut:
ppublish
Résumé
Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear. Patients with CRPM undergoing complete cytoreduction in 2005-2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes. Of 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33-6.12, p = 0.007], Sugarbaker's Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04-7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21-5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11-3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20-0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates. In patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population.
Sections du résumé
BACKGROUND
BACKGROUND
Selected patients with colorectal cancer peritoneal metastasis (CRPM) and extraperitoneal disease could be treated radically with a multimodal approach combining complete cytoreductive surgery, thermoablation, radiotherapy, and systemic and intraperitoneal chemotherapy. The impact of extraperitoneal metastatic sites (EPMS) in this setting remains unclear.
PATIENTS AND METHODS
METHODS
Patients with CRPM undergoing complete cytoreduction in 2005-2018 were grouped in: peritoneal disease only (PDO), one EPMS (1 + EPMS), two or more EPMS (2 + EPMS). A retrospective analysis compared overall survival (OS) and postoperative outcomes.
RESULTS
RESULTS
Of 433 patients, 109 had 1 + EPMS and 31 had 2 + EPMS. Overall, 101 patients had liver metastasis, 19 lung metastasis, and 30 retroperitoneal lymph node (RLN) invasion. The median OS was 56.9 months. There was no significant OS difference between PDO and 1 + EPMS groups (64.6 and 57.9 months, respectively), whereas OS was lower in the 2 + EPMS group (29.4 months, p = 0.005). In multivariate analysis, 2 + EPMS [hazard ratio (HR) 2.86, 95% confidence interval (CI) 1.33-6.12, p = 0.007], Sugarbaker's Peritoneal Carcinomatosis Index (PCI) > 15 (HR 3.86, 95% CI 2.04-7.32, p < 0.001), poorly differentiated tumors (HR 2.62, 95% CI 1.21-5.66, p = 0.015), and BRAF mutation (HR 2.10, 95% CI 1.11-3.99, p = 0.024) were independent poor prognostic factors, while adjuvant chemotherapy was beneficial (HR 0.33, 95% CI 0.20-0.56, p < 0.001). Patients with liver resection did not show higher severe complication rates.
CONCLUSION
CONCLUSIONS
In patients with CRPM selected for a radical surgical approach, limited extraperitoneal disease involving one site, notably the liver, does not seem to significantly impair postoperative results. RLN invasion appeared as a poor prognostic factor in this population.
Identifiants
pubmed: 36864324
doi: 10.1245/s10434-023-13279-9
pii: 10.1245/s10434-023-13279-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4444-4454Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Moretto R, Rossini D, Zucchelli G, et al. Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy–a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer. 2020;139:81–9.
doi: 10.1016/j.ejca.2020.08.009
pubmed: 32979645
Cutsem EV, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann oncol. 2016;27:1386–422.
doi: 10.1093/annonc/mdw235
pubmed: 27380959
Holch JW, Demmer M, Lamersdorf C, et al. Pattern and dynamics of distant metastases in metastatic colorectal cancer. Visc Med. 2017;33:70–5.
doi: 10.1159/000454687
pubmed: 28612020
pmcid: 5465778
Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19.
doi: 10.1016/S1470-2045(16)30500-9
pubmed: 27743922
Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–66.
doi: 10.1016/S1470-2045(20)30599-4
pubmed: 33476595
Goere D, Malka D, Tzanis D, et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg. 2013;257:1065–71.
doi: 10.1097/SLA.0b013e31827e9289
pubmed: 23299520
Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.
doi: 10.1046/j.1365-2168.2002.02274.x
pubmed: 12445064
Dico RL, Faron M, Yonemura Y, et al. Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2021;47:89–100.
doi: 10.1016/j.ejso.2020.07.038
pubmed: 32943276
Pinto A, Hobeika C, Philis A, et al. Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: different strategies for curative treatment? Langenbecks Arch Surg. 2019;404:477–88.
doi: 10.1007/s00423-019-01787-w
pubmed: 31025165
de Cuba EMV, Kwakman R, Knol DL, et al. Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. Cancer Treat Rev. 2013;39:321–7.
doi: 10.1016/j.ctrv.2012.11.003
pubmed: 23244778
Cremolini C, Antoniotti C, Stein A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;38:JCO2001225.
Rossini D, Antoniotti C, Lonardi S, et al. Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS/BRAF wild-type metastatic colorectal cancer: the phase III TRIPLETE study by GONO. J Clin Oncol. 2022;40:2878–88.
doi: 10.1200/JCO.22.00839
pubmed: 35666229
pmcid: 9426812
Molla M, Fernandez-Plana J, Albiol S, et al. Limited liver or lung colorectal cancer metastases. Systemic treatment, surgery, ablation or SBRT. J Clin Med. 2021;10:2131.
doi: 10.3390/jcm10102131
pubmed: 34069240
pmcid: 8157146
Kepenekian V, Bhatt A, Péron J, et al. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol. 2022;1–21.
Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations—part I: preoperative and intraoperative management. Eur J Surg Oncol. 2020;46:2292–310. https://doi.org/10.1016/j.ejso.2020.07.041 .
doi: 10.1016/j.ejso.2020.07.041
pubmed: 32873454
Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in Cytoreductive Surgery (CRS) with or without hyperthermic IntraPEritoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) society recommendations—part II: postoperative management and special considerations. Eur J Surg Oncol. 2020;46:2311–23. https://doi.org/10.1016/j.ejso.2020.08.006 .
doi: 10.1016/j.ejso.2020.08.006
pubmed: 32826114
Boukili IE, Flaris AN, Mercier F, et al. Prehabilitation before major abdominal surgery: evaluation of the impact of a perioperative clinical pathway, a pilot study. Scand J Surg. 2022;111:145749692210833.
doi: 10.1177/14574969221083394
Mohkam K, Passot G, Cotte E, et al. Resectability of peritoneal carcinomatosis: learnings from a prospective cohort of 533 consecutive patients selected for cytoreductive surgery. Ann Surg Oncol. 2016;23:1261–70.
doi: 10.1245/s10434-015-5005-2
pubmed: 26628435
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.
doi: 10.1007/978-1-4613-1247-5_23
pubmed: 8849962
Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.
doi: 10.1097/00000658-199501000-00004
pubmed: 7826158
pmcid: 1234492
Mercier F, Mohamed F, Cazauran J-B, et al. An update of peritonectomy procedures used in cytoreductive surgery for peritoneal malignancy. Int J Hyperth. 2019;36:744–52.
doi: 10.1080/02656736.2019.1635717
Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.
doi: 10.1245/ASO.2003.01.018
pubmed: 14527903
Alyami M, Kim BJ, Villeneuve L, et al. Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Hyperthermia. 2017;34:1–6.
Bakkers C, Lurvink RJ, Rijken A, et al. Treatment strategies and prognosis of patients with synchronous or metachronous colorectal peritoneal metastases: a population-based study. Ann Surg Oncol. 2021;28:9073–83.
doi: 10.1245/s10434-021-10190-z
pubmed: 34076807
pmcid: 8591028
Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358–63.
doi: 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O
pubmed: 10640968
Chandy ETJ, Saxby HJ, Pang JW, Sharma RA. The multidisciplinary management of oligometastases from colorectal cancer: a narrative review. Ann Palliat Med. 2021;10:5988–6001.
doi: 10.21037/apm-20-919
pubmed: 32921074
Deng K, Yang C, Tan Q, et al. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol. 2018;150:460–5.
doi: 10.1016/j.ygyno.2018.06.022
pubmed: 30001833
Han K-R, Pantuck AJ, Bui MHT, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61:314–9.
doi: 10.1016/S0090-4295(02)02163-5
pubmed: 12597937
Chen K, Deng X, Yang Z, et al. Sites of distant metastases and the cancer-specific survival of metastatic Siewert type II esophagogastric junction adenocarcinoma: a population-based study. Expert Rev Gastroent. 2020;14:491–7.
doi: 10.1080/17474124.2020.1760839
Jobsen JJ, ten Cate LN, Lybeert MLM, et al. The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor. Gynecol Oncol. 2010;117:32–6.
doi: 10.1016/j.ygyno.2009.12.010
pubmed: 20060158
van der Werf LR, Wassenaar E, de Niet A, et al. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. Eur J Surg Oncol. 2019;45:376–82.
doi: 10.1016/j.ejso.2018.10.540
pubmed: 30414704
Gagnière J, Dupré A, Chabaud S, et al. Retroperitoneal nodal metastases from colorectal cancer: Curable metastases with radical retroperitoneal lymphadenectomy in selected patients. Eur J Surg Oncol. 2015;41:731–7.
doi: 10.1016/j.ejso.2015.03.229
pubmed: 25899983
Bae SU, Hur H, Min BS, et al. Which patients with isolated para-aortic lymph node metastasis will truly benefit from extended lymph node dissection for colon cancer? Cancer Res Treat. 2017;50:712–9.
doi: 10.4143/crt.2017.100
pubmed: 28707461
pmcid: 6056972
Salah S, Ardissone F, Gonzalez M, et al. Pulmonary metastasectomy in colorectal cancer patients with previously resected liver metastasis: pooled analysis. Ann Surg Oncol. 2015;22:1844–50.
doi: 10.1245/s10434-014-4173-9
pubmed: 25326396
Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256:125–9.
doi: 10.1097/SLA.0b013e318255486a
pubmed: 22580942